Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Atai Life Sciences N.V.
(NQ:
ATAI
)
1.945
-0.035 (-1.77%)
Streaming Delayed Price
Updated: 1:50 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Atai Life Sciences N.V.
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
April 17, 2024
Via
Benzinga
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
April 15, 2024
The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
April 12, 2024
The 5 constituents in the Psychedelic Compound-Based Drug Stocks Index were up 10.0%, on average, last week and are now up 53.9% YTD.
Via
Talk Markets
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
April 03, 2024
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Recap: ATAI Life Sciences Q4 Earnings
March 28, 2024
Via
Benzinga
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
April 03, 2024
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly...
Via
Benzinga
Exposures
Glyphosate
March Recap: Largest Psychedelic Drug Stocks Up Another 5%
March 30, 2024
The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD.
Via
Talk Markets
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
March 29, 2024
Via
Benzinga
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
March 29, 2024
Via
Benzinga
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
March 28, 2024
Via
Benzinga
ATAI Stock Earnings: ATAI Life Sciences Beats EPS, Misses Revenue for Q4 2023
March 28, 2024
ATAI stock results show that ATAI Life Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
March 20, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
March 16, 2024
Via
Benzinga
Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
March 11, 2024
The FDA has granted breakthrough designation to Mind Medicine's program for the treatment of generalized anxiety disorder.
Via
Talk Markets
Exposures
Product Safety
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
March 04, 2024
Via
Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD
March 01, 2024
The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%.
Via
Talk Markets
Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
February 18, 2024
IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking...
Via
Talk Markets
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
February 15, 2024
Via
Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
February 15, 2024
Via
Benzinga
5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week
January 30, 2024
The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD.
Via
Talk Markets
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...
Via
Benzinga
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.
Via
Benzinga
5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week
January 13, 2024
The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD.
Via
Talk Markets
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
January 12, 2024
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Via
Benzinga
Therapy’s New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution
January 09, 2024
Psychedelic stocks have been making big moves beneath the surface, and the sector's popularity might spark again in 2024.
Via
InvestorPlace
3 Big New Catalysts for Psychedelics Stocks in 2024
January 08, 2024
This could be the year that psychedelics stocks start to fly.
Via
The Motley Fool
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
January 07, 2024
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury
Via
Benzinga
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
January 06, 2024
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub
Via
Benzinga
Atai Life Sciences Shows Positive Results In Phase 1 Clinical Study For PTSD Treatment
January 04, 2024
Biopharma company Atai Life Sciences (NASDAQ: ATAI) shared positive results from a Phase 1 clinical study on MDMA R-enantiomer, EMP-01, under development for the potential treatment of PTSD.
Via
Benzinga
Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Development
January 04, 2024
Biopharma and resources-pooling company Atai Life Sciences (NASDAQ: ATAI) has invested a total of $50 million in Beckley Psytech Ltd., a U.K.-based clinical-stage biotech advancing short-duration...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.